S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
CVSI · CV Sciences, Inc.
OTC MARKETS - Real Time Price • USD
$0.01
-0.00
(-10.71%)
● Overnight
DAY'S RANGE
$0.01
$0.01
$0.01
52-WEEK RANGE
$0.01
$0.01
$0.10
What's happening
- CVSI is down 10.71% today, trading at $0.01. — Live quote
- It's trading within 3% of its 52-week low ($0.01). (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 0
Buy 0
Hold 3
Sell 1
Strong sell 2
Aggregate ratings for 2023-03-01 (6 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
CVSI
-83.71%
vs S&P 500
-96.49%
1-YEAR RETURN
CVSI
-71.75%
vs S&P 500
-86.31%
6-MONTH RETURN
CVSI
-65.52%
3-MONTH RETURN
CVSI
-49.49%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-01-26 (Q4 2025)
$0.00
Est. $—
2025-01-26 (Q4 2024)
$0.00
Est. $—
2024-10-26 (Q3 2024)
$0.00
Est. $—
2024-07-26 (Q2 2024)
$0.00
Est. $—
Valuation Measures & Ratios
Enterprise Value4$3.0M
Forward P/E5—
PEG Ratio6-0.05
Price / Sales (TTM1)0.18
Price / Book73.16
EV4 / Revenue0.24
EV4 / EBITDA0.84
Profit Margin-15.74%
Operating Margin-8.26%
Return on Equity (ROE8)-132.06%
Return on Assets (ROA9)-29.50%
Avg Volume (3M)653,480
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short14,190
Change from Prior Settlement+123.11%
% of Float—
Days to Cover (Short Ratio)1.00
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-09-09; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -17.5% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -15.7%. Finnhub fundamentals ↗
- Trailing 52-week price return is -71.8%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on CVSI
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.0M | $3.2M | $3.3M | $3.6M | $3.6M | $3.9M | $4.0M | $4.0M |
| Gross profit | $1.4M | $1.6M | $1.6M | $1.8M | $1.7M | $1.8M | $1.9M | $1.9M |
| Operating income | -$301.0K | -$318.0K | -$275.0K | -$131.0K | $11.0K | -$341.0K | -$583.0K | -$620.0K |
| Net income | -$775.0K | -$643.0K | -$382.0K | -$261.0K | -$109.0K | -$456.0K | -$584.0K | -$628.0K |
| EPS (diluted) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS (basic) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating margin | -$10 | -$10 | -$8 | -$4 | $0 | -$9 | -$15 | -$15 |
| Net margin | -$26 | -$20 | -$12 | -$7 | -$3 | -$12 | -$15 | -$16 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $6.5M | $6.7M | $7.0M | $7.0M | $8.0M | $7.8M | $7.9M | $8.4M |
| Total liabilities | $5.0M | $5.2M | $5.5M | $5.5M | $6.1M | $5.9M | $6.1M | $6.2M |
| Stockholders' equity | $1.6M | $1.5M | $1.5M | $1.5M | $1.8M | $1.9M | $1.8M | $2.2M |
| Total current assets | $4.9M | $5.0M | $5.1M | $5.1M | $5.9M | $6.0M | $6.2M | $6.7M |
| Total current liabilities | $4.9M | $5.2M | $5.0M | $4.8M | $5.7M | $5.3M | $6.1M | $6.1M |
| Cash & equivalents | — | — | — | — | — | — | — | — |
| Accounts receivable | $348.0K | $391.0K | $402.0K | $405.0K | $545.0K | $430.0K | $522.0K | $422.0K |
| Inventory | $4.0M | $3.9M | $4.1M | $4.1M | $4.2M | $4.4M | $4.9M | $5.0M |
| Other current assets | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $319.0K | $329.0K | $344.0K | $349.0K | $363.0K | $364.0K | $399.0K | $490.0K |
| Goodwill | $999.0K | $1.0M | $1.0M | $1.0M | $1.0M | $988.0K | $971.0K | $815.0K |
| Intangible assets | $62.0K | $68.0K | $76.0K | $82.0K | $88.0K | $90.0K | $93.0K | $103.0K |
| Other non-current assets | $47.0K | $47.0K | $47.0K | $47.0K | $72.0K | $99.0K | $127.0K | $154.0K |
| Accounts payable | $1.1M | $1.1M | $1.0M | $1.2M | $1.4M | $1.5M | $1.9M | $1.9M |
| Accrued liabilities | $2.6M | $2.6M | $2.4M | $2.9M | $3.0M | $2.8M | $3.4M | $3.4M |
| Short-term debt | $18.0K | $72.0K | $1.3M | $451.0K | $1.0M | $770.0K | $677.0K | — |
| Long-term debt | $0 | $0 | $387.0K | $504.0K | $208.0K | $498.0K | $0 | — |
| Other non-current liabilities | — | — | — | — | — | — | $0 | $38.0K |
| Common stock & paid-in capital | $21.0K | $19.0K | $18.0K | $18.0K | $18.0K | $18.0K | $18.0K | $18.0K |
| Retained earnings | -$89.4M | -$88.6M | -$87.9M | -$87.7M | -$87.4M | -$87.1M | -$87.0M | -$86.3M |
| Accumulated other comprehensive income (loss) | $26.0K | $32.0K | $59.0K | $47.0K | $53.0K | $13.0K | -$15.0K | $19.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $20.0K | $101.0K | -$354.0K | -$259.0K | $287.0K | -$81.0K | -$164.0K | -$122.0K |
| Investing cash flow | -$7.0K | -$3.0K | -$9.0K | -$11.0K | -$49.0K | -$40.0K | -$22.0K | $34.0K |
| Financing cash flow | -$54.0K | -$68.0K | $258.0K | -$234.0K | -$167.0K | $480.0K | -$335.0K | $590.0K |
| Free cash flow | $13.0K | $98.0K | -$363.0K | -$270.0K | $238.0K | -$121.0K | -$182.0K | -$122.0K |
| Capital expenditures | $7.0K | $3.0K | $9.0K | $11.0K | $49.0K | $40.0K | $18.0K | $0 |
| Depreciation & amortization | $22.0K | $23.0K | $21.0K | $31.0K | $58.0K | $82.0K | $114.0K | $81.0K |
| Share-based compensation | $148.0K | $148.0K | $123.0K | $124.0K | $132.0K | $118.0K | $104.0K | $87.0K |
| Deferred income taxes | — | — | $3.0K | — | — | — | -$15.0K | — |
| Change in accounts receivable | -$44.0K | -$22.0K | $6.0K | -$142.0K | $112.0K | -$100.0K | $103.0K | -$219.0K |
| Change in inventory | $64.0K | -$174.0K | $3.0K | -$132.0K | -$162.0K | -$536.0K | -$114.0K | -$176.0K |
| Change in accounts payable | — | — | — | — | — | — | — | — |
| Purchases of investments | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $13.8M | $15.7M | $16.0M | $16.2M | $20.0M |
| Gross profit | $6.8M | $7.2M | $7.1M | $5.5M | $8.6M |
| Operating income | -$470.0K | -$2.2M | $3.4M | -$6.8M | -$18.4M |
| Net income | -$958.0K | -$2.4M | $3.1M | -$8.2M | -$15.6M |
| EPS (diluted) | $-0.01 | $-0.01 | $0.02 | $-0.07 | $-0.14 |
| EPS (basic) | $-0.01 | $-0.01 | $0.02 | $-0.07 | $-0.14 |
| Operating margin | -$3 | -$14 | $21 | -$42 | -$92 |
| Net margin | -$7 | -$15 | $19 | -$51 | -$78 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $7.0M | $7.9M | $9.2M | $12.7M | $18.1M |
| Total liabilities | $5.5M | $6.1M | $6.3M | $13.5M | $14.5M |
| Stockholders' equity | $1.5M | $1.8M | $2.9M | -$777.0K | $3.5M |
| Total current assets | $5.1M | $6.2M | $7.9M | $11.1M | $14.2M |
| Total current liabilities | $5.0M | $6.1M | $6.1M | $13.3M | $14.5M |
| Cash & equivalents | — | — | — | $611.0K | $1.4M |
| Accounts receivable | $402.0K | $522.0K | $431.0K | $766.0K | $2.0M |
| Inventory | $4.1M | $4.9M | $5.7M | $6.6M | $8.6M |
| Other current assets | — | — | — | — | — |
| Property, plant & equipment | $344.0K | $399.0K | $379.0K | $575.0K | $1.7M |
| Goodwill | $1.0M | $971.0K | $342.0K | $0 | $0 |
| Intangible assets | $76.0K | $93.0K | $78.0K | $251.0K | — |
| Other non-current assets | $47.0K | $127.0K | $296.0K | $505.0K | $678.0K |
| Accounts payable | $1.0M | $1.9M | $2.3M | $2.3M | $2.6M |
| Accrued liabilities | $2.4M | $3.4M | $3.4M | $9.7M | $10.9M |
| Short-term debt | $1.3M | $677.0K | — | — | $310.0K |
| Long-term debt | $387.0K | $0 | — | — | $0 |
| Other non-current liabilities | — | $0 | $105.0K | $0 | — |
| Common stock & paid-in capital | $18.0K | $18.0K | $16.0K | $15.0K | $11.0K |
| Retained earnings | -$87.9M | -$87.0M | -$84.6M | -$87.7M | -$79.5M |
| Accumulated other comprehensive income (loss) | $59.0K | -$15.0K | $10.0K | $0 | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$407.0K | -$861.0K | $2.3M | -$1.9M | -$7.5M |
| Investing cash flow | -$109.0K | -$28.0K | -$156.0K | $0 | -$35.0K |
| Financing cash flow | $337.0K | $32.0K | -$1.4M | $1.1M | $4.4M |
| Free cash flow | -$516.0K | -$879.0K | $2.3M | -$1.9M | -$7.5M |
| Capital expenditures | $109.0K | $18.0K | $0 | $0 | $35.0K |
| Depreciation & amortization | $192.0K | $334.0K | $235.0K | $992.0K | $1.2M |
| Share-based compensation | $497.0K | $258.0K | $218.0K | $1.0M | $3.2M |
| Deferred income taxes | $3.0K | -$15.0K | -$14.0K | -$51.0K | -$94.0K |
| Change in accounts receivable | -$124.0K | $84.0K | -$352.0K | -$1.1M | $989.0K |
| Change in inventory | -$827.0K | -$803.0K | -$1.0M | -$2.1M | -$216.0K |
| Change in accounts payable | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding CVSI as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2021-01-06 to 2026-08-07
Recent transactions
- Insiders have net bought 5,740,816 shares over the last 182 days, across 10 purchases and 0 sales.
- Most recent: CHEEVER CHARLIE E III (10% owner) — Open market purchase of 94,854 shares on 2026-08-07.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)5,740,816 sh(10 txns)
Sales (open market)0 sh(0 txns)
Net Shares+5,740,816
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| CHEEVER CHARLIE E III | 10% owner | Open market purchase | 2026-08-07 | 94,854 |
| MAROON JOSEPH C MD | Director | Open market purchase | 2021-05-21 | 50,000 |
| Mona Michael Joseph Jr | 10% owner | Open market sale | 2021-01-15 | 16,600 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-07 | CHEEVER CHARLIE E III | 10% owner | Open market purchase | 94,854 | $0.02 |
| 2026-08-04 | CHEEVER CHARLIE E III | 10% owner | Open market purchase | 108,000 | $0.02 |
| 2026-07-31 | CHEEVER CHARLIE E III | 10% owner | Open market purchase | 1,730,000 | $0.02 |
| 2026-07-29 | CHEEVER CHARLIE E III | 10% owner | Open market purchase | 60,000 | $0.02 |
| 2026-07-28 | CHEEVER CHARLIE E III | 10% owner | Open market purchase | 1,830,000 | $0.02 |
| 2026-07-24 | CHEEVER CHARLIE E III | 10% owner | Open market purchase | 470,075 | $0.02 |
| 2026-07-22 | CHEEVER CHARLIE E III | 10% owner | Open market purchase | 272,500 | $0.02 |
| 2026-07-21 | CHEEVER CHARLIE E III | 10% owner | Open market purchase | 335,000 | $0.02 |
| 2026-07-17 | CHEEVER CHARLIE E III | 10% owner | Open market purchase | 749,000 | $0.02 |
| 2026-07-16 | CHEEVER CHARLIE E III | 10% owner | Open market purchase | 91,387 | $0.02 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 22:53 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-09 | 4 | 2026-07-16 | View on SEC.gov → |
| 2026-08-13 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-13 | 8-K | 2026-05-14 | View on SEC.gov → |
| 2026-06-04 | 8-K | 2025-03-27 | View on SEC.gov → |
| 2026-05-15 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-14 | 8-K | 2026-05-14 | View on SEC.gov → |
| 2026-04-10 | 8-K | 2026-04-06 | View on SEC.gov → |
| 2026-03-26 | 10-K | 2025-12-31 | View on SEC.gov → |
| 2026-03-26 | 8-K | 2026-03-26 | View on SEC.gov → |
| 2026-03-10 | 8-K | 2025-10-07 | View on SEC.gov → |
| 2025-11-13 | 10-Q | 2025-09-30 | View on SEC.gov → |
| 2025-11-13 | 8-K | 2025-11-13 | View on SEC.gov → |
Recent news
Headlines about CVSI (CV Sciences, Inc.). Links open the publisher — we don’t host full articles.
-
CV Sciences Welcomes Enactment of Federal Legislation Providing Additional Time for a Responsible, Science-Based Hemp Regulatory Framework
Yahoo Finance · 2026-09-08 -
CV Sciences Inc (CVSI) (Q2 2026) Earnings Call Highlights: Strategic Pivot to PlusHealth Amid ...
Yahoo Finance · 2026-08-17 -
CV Sciences outlines hemp-rule delay to December 11, 2026 while expanding PlusHLTH.com and planning multiple 2026 launches
Seeking Alpha · 2026-08-13 -
CV Sciences, Inc. (CVSI) Q2 2026 Earnings Call Transcript
Seeking Alpha · 2026-08-13 -
CV Sciences, Inc. Reports Second Quarter-End 2026 Financial Results
Yahoo Finance · 2026-08-13 -
CV Sciences Launches PlusHLTH.com, Expanding Its Consumer Platform Beyond Cannabinoids
Yahoo Finance · 2026-08-12 -
CV Sciences, Inc. to Announce Second Quarter 2026 Results on August 13, 2026
Yahoo Finance · 2026-08-11 -
CV Sciences Expands +PlusHLTH(TM) Portfolio with Personalized Wellness Solutions for Healthy Aging
Yahoo Finance · 2026-06-26
No headlines in this category right now — try “All”.